false
--12-31
0000719135
0000719135
2025-12-08
2025-12-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
December
8, 2025
Date
of Report (date of earliest event reported)

APYX
MEDICAL CORPORATION
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-31885 |
|
11-2644611 |
(State
or other jurisdiction
of
incorporation or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
5115
Ulmerton Road, Clearwater, Florida 33760
(Address
of principal executive offices, zip code)
(727)
384-2323
Registrant’s
telephone number, including area code
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
APYX |
|
Nasdaq
Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item
5.03. | Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
As
previously reported, Apyx Medical Corporation (the “Company”) held its Annual Meeting of Stockholders on August 7, 2025,
at which the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended (“Certificate
of Incorporation”), to remove Article EIGHTH in its entirety and replace it with “intentionally omitted.” (the “Amendment”).
On
December 8, 2025, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the
State of Delaware to effect the Amendment.
For
more information about the Amendment, see the Company’s definitive proxy statement filed with the U.S. Securities and Exchange
Commission on June 25, 2025, the relevant portions of which are incorporated herein by reference. The information set forth herein is
qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current
Report on Form 8-K.
| Item
9.01. |
Financial
Statements and Exhibits. |
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Certificate of Incorporation of Apyx Medical Corporation. |
| 104 |
|
Cover
Page Interactive Data File embedded within the Inline XBRL document |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
APYX
MEDICAL CORPORATION |
| |
|
|
| Date:
December 12, 2025 |
By:
|
/s/
Matthew Hill |
| |
Name:
|
Matthew
Hill |
| |
Title: |
Chief
Financial Officer, Secretary and Treasurer |